New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Kotton, Camille N.; Kamar, Nassim

doi:10.1007/s40121-022-00746-1

Cited by 30 publications

(32 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Letermovir, in contrast, was not associated with myelosuppression in the current study or previously among the HCT population . Other antiviral agents used for treatment of CMV disease in recipients of solid organ transplant, including foscarnet and cidofovir, are not realistic prevention alternatives due to the need for intravenous dosing and severe adverse events, including nephrotoxicity . Finally, letermovir has been reported to have a low barrier to resistance when used for active CMV infection; case reports have described the rapid development of letermovir resistance when used to treat resistant or refractory CMV disease .…”

mentioning

confidence: 50%

A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant

Raglow

Kaul

2023

JAMA

View full text Add to dashboard Cite

mentioning

confidence: 50%

A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant

Raglow

Kaul

2023

JAMA

View full text Add to dashboard Cite

“…Using an enzyme‐linked immunospot (ELISpot) assay, we observed that the numbers of the secreted IFN‐ γ spots were significantly more when the stimulated CTLs responding to T2 cells loaded with six individually predicted neoantigens (peptide SI, AP1G1, UGT2B10, TPST1, OR2G2, and TGIF2LX) compared to DMSO ( Figure A,B). Three previously validated peptides, cytomegalovirus (peptide CMV), [ 32 ] virus‐associated antigen (peptide HCV: NS3), [ 33 ] and HCC‐associated antigen (peptide VEGFR2‐190), [ 34 ] were recruited as positive control peptides. We also detected the immunogenicity of other candidate neoantigen peptides, and most of them did not show significant differences compared to the control group (Figure S2, Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

Engineering In Vitro Organ‐Structured Tumor Model for Evaluating Neoantigen‐Specific T Cell Responses in Hepatocellular Carcinoma

Xiao

Wang

et al. 2023

Adv Materials Inter

View full text Add to dashboard Cite

Neoantigens derived from somatic mutations in cancer cells can induce antigen‐specific T‐cell immune response for cancer immunotherapy. However, the 3D models for assessing neoepitope immunogenicity and efficacy of anti‐tumor T‐cell immune response to neoantigens are less than perfect. Here, a 3D tumor model based on recellularized liver matrix is leveraged with HepG2 cells to investigate T cell cytotoxic reactivity toward hepatocellular carcinoma (HCC) neoantigens. The whole exome sequencing (WES) data of 364 HCC patients in The Cancer Genome Atlas database are collected and 25 highly potential immunogenic neoantigens to human leukocyte antigen (HLA)‐A*02:01 molecule in silico are predicted. Six of the HCC neoantigen candidates are functionally validated with high immunogenicity by measuring cellular interferon‐γ secretion and cytotoxicity during neoantigen‐specific T‐cell immune responses in vitro. Then, the minigene of six functionally identified neoantigen peptides is constructed and the minigene‐modified GFP‐HepG2 cells are generated. Neoantigen‐specific immune response is observed with highly secreted Granzyme B, IFN‐γ, and PD‐1 when targeting the minigene‐modified GFP‐HepG2 cells in the 3D RLM HCC tumor model. Overall, the 3D RLM tumor model provides a novel strategy for preclinical assessment of the efficacy of neoantigen‐specific T cell immune response, which helps develop personalized cancer vaccines and immunotherapy treatments for HCC patients.

show abstract

“…Letermovir, a selective terminase inhibitor, is a new anti-CMV drug that inhibits the formation and release of viral particles and has a lower rate of myelotoxicity. It was previously approved for prophylaxis in hemopoietic stem cell transplant (HSCT) patients [ 16 ]. A review of the literature showed that IgG4-related oesophageal disease with cytomegalovirus infection is very rare.…”

Section: Introductionmentioning

confidence: 99%

IgG4-Related Oesophageal Disease with Cytomegalovirus Infection: A Case Report

Zhang

Lai

et al. 2023

JPM

View full text Add to dashboard Cite

Immunoglobulin G4-related disease (IgG4-RD) is a fibrous inflammatory process related to immunomodulation. The involvement of the pancreato-biliary tract, retroperitoneum/aorta, head and neck, and salivary glands are the most frequently observed disease phenotypes, differing in their epidemiological features, serological findings, and prognostic outcomes. IgG4-RD was combined with oesophageal ulcers, and the patients were infected with cytomegalovirus at the time of the examination. This constituted a huge challenge in the diagnosis and treatment of oesophageal ulcers. We report the case of a 53-year-old male who experienced nausea, vomiting, and anaemia recurrently for many years. According to his medical records, an upper gastrointestinal endoscopy revealed an oesophageal ulcer, and he had had numerous hospital visits for anaemia but with no definitive diagnosis, and he had responded poorly to therapy. However, with persistent symptoms, he came to our hospital and, according to the results of the upper gastrointestinal endoscopy, a serum IgG4 test, and histopathological and immunohistochemical staining, he was finally diagnosed with IgG4-related oesophageal disease combined with a cytomegalovirus infection. We hope that through this case, we can learn more about IgG4-RD and, at the same time, give clinicians a better understanding of IgG4-RD combined with oesophageal ulceration, a new understanding of cytomegalovirus infections, and improved clinical knowledge.

show abstract

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Cited by 30 publications

References 54 publications

A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant

A New Antiviral Option for Cytomegalovirus Prevention After Kidney Transplant

Engineering In Vitro Organ‐Structured Tumor Model for Evaluating Neoantigen‐Specific T Cell Responses in Hepatocellular Carcinoma

IgG4-Related Oesophageal Disease with Cytomegalovirus Infection: A Case Report

Contact Info

Product

Resources

About